View clinical trials related to Cardiac Event.
Filter by:Advanced remote multi-parameter reporting during cardiac rehabilitation (MAPS-III). The primary purpose of this observational study is to collect baseline information of cardiac rehabilitation usage in the US for post-myocardial infarction (MI) patients with EF > 35% while wearing the ZOLL AMS device for 30 to 60 days. Secondary data on biometrics, arrhythmias, symptoms, and healthcare utilization will provide additional background information on this population during the early post-MI cardiac rehabilitation period.
The aim of current study is to compare safety and efficacy of lansoprazole/domperidone 30/30 mg sustained release capsules (brand name: Duolans) and lansoprazole 30 mg micropellet capsules (brand name: Lasotab) in GERD patients in terms of cardiac safety.
- To evaluate plasma concentrations of Cefuroxime in this patient population - To determine if certain pathophysiological and/or iatrogenic conditions alter the pharmacokinetics in this patient group. - To develop a rational physiological population pharmacokinetic model that describes plasma concentrations of medications in these patients.